For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

The FLT3 receptor is overexpressed on the majority of acute myeloid leukemia (AML) blasts.
Mutations in FLT3 are the most common genetic alteration in AML, identified in …

Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults
and accounts for the largest number of annual deaths due to leukemias in the United States …

The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in approximately one third of patients
with acute myeloid leukemia (AML), either by internal tandem duplications (FLT3-ITD), or by …

FMS‐like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase that plays an
important role in hematopoietic cell survival, proliferation and differentiation. The most …

Background Preclinical data and results from non-randomised trials suggest that the
multikinase inhibitor sorafenib might be an effective drug for the treatment of acute myeloid …

The objective was to evaluate the prognostic and predictive impact of allelic ratio and
insertion site (IS) of internal tandem duplications (ITDs), as well as concurrent gene …

Approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML) harbor
mutations in the fms-like tyrosine kinase 3 (FLT3) gene. While the adverse prognostic impact …

PURPOSE High allelic ratio (HAR) FLT3/ITD (AR> 0.4) mutations confer poor prognosis in
pediatric acute myeloid leukemia (AML). COG AAML1031 studied the feasibility and efficacy …